Aktuelle Systemtherapie beim Nierenzellkarzinom

In der Vergangenheit war die medikamentöse Therapie des metastasierten oder lokal fortgeschrittenen, nichtoperablen Nierenzellkarzinoms vor allem durch den Einsatz von Tyrosinkinase-Inhibitoren dominiert. Aktuell rücken Checkpoint-Inhibitoren und moderne Multikinase-Inhibitoren in den Vordergrund der Erstlinientherapie.

Publikationsverlauf

Artikel online veröffentlicht:
03. August 2020

• Literatur

• 1 Heng DY, Xie W, Regan MM. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799
• 2 Motzer RJ, Bacik J, Murphy BA. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296
• 3 Motzer RJ, Mazumdar M, Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540
• 4 Goebell PJ, Müller L, Staehler M. et al. Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry. Oncol Res Treat 2017; 40: S3
• 5 Procopio G, Bamias A, Schmidinger M. et al. Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL Study). Ann Oncol 2018; 29 (Suppl. 08) viii303-viii331
• 6 Motzer RJ, Tannir NM, McDermott DF. et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378: 1277-1290
• 7 Tannir NM, McDermott DF, Escudier B. et al Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). Journal of Clinical Oncology 2020; 38 (Suppl. 06) 609-609 , doi:10.1200/JCO.2020.38.6_suppl.609
• 8 Motzer RJ, Hutson TE, McCann L. et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370: 1769-1770
• 9 Motzer RJ, Nosov D, Eisen T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial. J Clin Oncol 2013; 31: 3791-3799
• 10 Motzer RJ, Escudier B, Powles T. et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 2018; 118: 1176-1178
• 11 Rini BI, Plimack ER, Stus V. et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1116-1127
• 12 Motzer RJ, Penkov K, Haanen J. et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1103-1115
• 13 Plimack ER. Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma (RCC): Updated Analysis of KEYNOTE-426. Journal of Clinical Oncology 2020; 38 (Suppl. 15) 5001-5001 , doi:10.1200/JCO.2020.38.15_suppl.5001
• 14 Choueiri TK, Motzer RJ, Rini BI. et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma [published online ahead of print, 2020 Apr 25]. Ann Oncol 2020; S0923-7534(20)39308-X
• 15 Motzer RJ, Escudier B, McDermott DF. et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med 2015; 373: 1803-1813
• 16 Motzer RJ, Hutson TE, Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicenter trial. Lancet Oncol 2015; 16: 1473-1482